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Oncogenic potential
Proteasomal degradationLytic infection and transformation of cultured cells by JC virus (JCV) requireﬁve tumor proteins, which interactwith
factors regulating critical cellular processes.We demonstrate that JCV large T antigen (TAg) binds the F-box proteins
β-transducin-repeat containing protein-1 and 2 (βTrCP1/2). These interactions involve a phosphodegron
(DpSGX2–4pS) found in βTrCP substrates. TAg stability is unaltered, suggesting TAg is a pseudo-substrate. βTrCP
and TAg co-localize in the cytoplasm, and a functional SCF complex is required. We examined whether TAg
inﬂuences the levels of β-catenin, a βTrCP substrate.Wewere unable to demonstrate that TAg elevates β-catenin as
previously reported, and a mutant TAg unable to bind βTrCP also had no detectable effect on β-catenin stability.
Results presented in this study link JCVTAg to the cellulardegradationcomplex, SCFβTrCP1/2. Proteasomaldegradation
is essential for proper regulation of cellular functions, and interference with proteasomal pathways highlights
possible JCV pathogenic and oncogenic mechanisms.ate University, University Park,
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
JCV, a member of the Polyomaviridae family of viruses, causes
asymptomatic infections in approximately 50% of the human population
(Kean et al., 2009). In immunocompromised individuals, the lytic
destruction of oligodendrocytes by JCV leads to demyelination within
the central nervous system and the fatal disease progressive multifocal
leukoencephalopathy (PML). Inoculation of JCV into rodents and non-
human primates results in tumor formation, and in humans JCV has been
associated with brain, lung and colon tumors (Frisque et al., 2006; Khalili
et al., 2006). JCV produces ﬁve tumor proteins: Large T Antigen (TAg),
small t Antigen (tAg), T′165, T′136 and T′135, which interact with several
cellular proteins including tumor suppressors. The 5 tumor proteins bind
differentially tomembers of the Retinoblastoma (Rb) family (Bollag et al.,
2000, 2006, 2010). Polyomavirus TAgs also interact with p53, inhibiting
this tumor suppressor's transcriptional activity and increasing its stability,
in part, by preventing its degradation via the E3 ubiquitin ligase, MDM-2
(reviewed in Levine, 2009). These events lead to cell cycleprogression and
contribute to the transforming potential of these viruses (Frisque et al.,
2006; reviewed in Pipas and Levine, 2001). In addition to binding Rb and
p53, TAg has been reported to bind β-catenin, resulting in β-catenin's
stabilization, translocation into the nucleus and increased transactivation
activity (Enam et al., 2002; Gan and Khalili, 2004). TAg also modulates
β-catenin stability and subcellular localization through Rac1 activation
(Bhattacharyya and Khalili, 2007). The regulation of cytosolic β-catenin isan essential step in the controlled functioning of the Wnt signaling
cascade. Degradation of β-catenin is achieved by its phosphorylation at
serine 45 by CK1α, and serine 33, serine 37 and threonine 41 by GSK3-β
(Kimelman and Xu, 2006). Phosphorylated β-catenin is recognized by
beta-transducin-repeat containing protein (βTrCP), an F-box containing
component of the Skp1–Cul1–F-box protein (SCF) E3 ubiquitin ligase
complex, and targeted for ubiquitination and proteasomal degradation
(Kimelman and Xu, 2006). Additional βTrCP substrates include Wee1
(Watanabeet al., 2004), Cdc25AandB(Businoet al., 2003;Kanemori et al.,
2005), IκB (Karin andBen-Neriah, 2000), and the tumor suppressors REST
(Westbrook et al., 2008) and Pdcd4 (Dorrello et al., 2006).
βTrCP2 (also called HOS), is an F-box protein that exhibits 86% amino
acid identitywithβTrCP1; the two proteins only differ in their N-terminal
sequences (Fuchs et al., 1999; Koike et al., 2000). βTrCP2 also targets
β-catenin and IκB for ubiquitination and proteasomal degradation,
demonstrating an overlap of function for the two proteins (Fuchs et al.,
1999). Nonetheless, some differences in the two proteins have been
recognized. For example, βTrCP2, but not βTrCP1, is essential for the
ubiquitination, degradation and down-regulation of the interferon-α
receptor (IFNAR1) (Kumar et al., 2003) and the prolactin receptor (PRLR)
(Li et al., 2004). The targeting of different substrates by the two F-box
proteins may be attributed, in part, to differences in their subcellular
localization; βTrCP1 resides primarily in the nucleus while βTrCP2 is
found in the cytoplasm (Davis et al., 2002; Fuchs et al., 2004).
βTrCP1 and βTrCP2 recognize most substrates via their phospho-
degron consensus sequence, DpSGX2–4pS. Phosphorylation of the
serine residues in this motif is required for βTrCP binding and for
subsequent linkage to the ubiquitination machinery (Laney and
Hochstrasser, 1999). We have identiﬁed a potential phosphodegron
Fig. 1. JCV TAg interactswithβTrCP1. Extracts fromU87MG cells co-transfectedwith pCMV-
JCVE (JCVE) or pCMV-T+/t−/T′− (TAg), and GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF)
plasmids were subjected to IP or GST pull down analyses. (A) Cell extracts (50 μg) were
immunoprecipitated with anti-T antibody (PAb962) and the viral proteins were detected
using an anti-T antibody cocktail. (B) Protein extracts (500 g) were analyzed for the
expression of GST, GST-βTrCP1 and GST-βTrCPΔF by GST pull down and detection with an
anti-GST antibody. (C) The interactions of TAg with βTrCP1 and βTrCPΔF were detected by
performing GST pull downs of cell extracts (500 μg) and immunoblotting with an anti-T
antibody cocktail (lanes 1, 4–9). Cell extracts (30 μg) containing either TAgor allﬁve JCVearly
proteins (JCVE) were immunoprecipitated with PAb962 followed by WB with an anti-T
antibody cocktail (lanes 2, 3). Mock-transfected U87MG cells were used as a control (Con).
Small proteins recognized by the anti-GST antibody are marked with two asterisks.
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studywe have examined and characterized the interaction that occurs
between JCV TAg and βTrCP, and investigatedwhether this interaction
alters the amount ofβ-catenin, aβTrCP substrate, found inmammalian
cells.
Results
JCV TAg interacts with βTrCP1
The multifunctional JCV TAg induces transformation of cells by
interacting with key cellular proteins involved in cell cycle regulation
and signal transduction. By scanning the primary sequence, we
identiﬁed a potential βTrCP binding domain at the C-terminus of TAg
(amino acids 639–645: DSGHGSS). To determinewhether TAg interacts
withβTrCP1,weperformedGSTpull downexperimentswith extracts of
U87MG cells co-transfected with pCMV-JCVE or pCMV-T+/t−/T′−, and
plasmids expressing either wild type (WT) GST-βTrCP1 or mutant
GST-βTrCPΔF.βTrCPΔF, a dominant negative form of βTrCP1, is missing
the F-box domain required for its interaction with components of the
SCF complex (Westbrook et al., 2008). Because βTrCP1 targets its
substrates for ubiquitination and degradation in the proteasome, we
examined the integrity of the viral tumor proteins in cell extracts
containing GST-βTrCP1 (Fig. 1A). The TAg expression level did not vary
detectably in the presence ofβTrCP1, suggesting that the stability of TAg
is not altered in the presence of the F-box protein.We also analyzed the
expression levels of the GST-tagged βTrCP1 and βTrCPΔF, and noticed
that the level of themutant protein was consistently higher than that of
WT βTrCP1 (Fig. 1B). In addition, protein bands ranging in size from 26
to34 kDaand recognizedby theanti-GST antibodyweredetected on the
Western blot (WB). These small peptides may result from partial
degradation of GST-βTrCP1, and deletion of the F-box domain might
confer increased stability to the βTrCPΔF protein. The GST pull down
assay (Fig. 1C) indicated that TAg, and no other T protein, binds both
βTrCP1 and βTrCPΔF in the presence (lanes 6, 8; respectively) or
absence (lanes 7, 9; respectively) of the other 4 early tumor proteins.
Because TAg interacts with βTrCPΔF (lanes 8, 9), which is unable to
interactwith the other components of the SCF complex,we conclude the
interaction between TAg and the F-box protein is direct and does not
occur through other members of the E3 ubiquitin ligase complex.
SV40 TAg does not interact with βTrCP1
The JCV and SV40 TAg sequences share 72% sequence identity
(Frisque and White, 1992), therefore we compared the primary
sequence of SV40 TAg with that of JCV TAg to determine if SV40 TAg
also possesses a βTrCP1 binding site. The C-terminus of SV40 TAg
contains the related sequence DSGHETG (amino acids 656–662). The
threonine at position 661 corresponds to serine 644 in the JCV TAg.
Bora, an essential mitotic protein involved in spindle formation, is a
known βTrCP1 target; it also has a threonine replacing the second
serine of the binding motif (Seki et al., 2008).
293T cells express SV40 early proteins and have been used in a
number of βTrCP1 studies (Dorrello et al., 2006; Kitagawa et al., 1999;
Sadot et al., 2000; Westbrook et al., 2008; Winston et al., 1999). If SV40
TAg did bind βTrCP1, such an interaction would likely inﬂuence
interpretations of data obtained in earlier studies. We performed GST
pull down experiments with extracts from 293T cells transfected with
the GST-βTrCP1 or GST-βTrCPΔF expressing constructs, orwith extracts
from the parental 293 cells co-transfected with pCMV-JCVE and either
the GST-βTrCP1 or GST-βTrCPΔF plasmid. WB analyses demonstrated
the presence of JCV and SV40 TAgs in 293 and 293T cells, respectively
(Fig. 2A), and of GST-βTrCP proteins in both cell lines (Fig. 2B). The GST
pull down analyses indicated that the SV40 TAg in 293T cells does not
interact with βTrCP1 nor βTrCPΔF (Fig. 2C, lanes 9, 11; respectively),
whereas JCV TAg binds both proteins in 293 cells (Fig. 2C, lanes 8, 10).These experiments were also performed in Cos-7 cells, an African green
monkey kidney line transformed by an origin-defective mutant of SV40
(Gluzman, 1981), and again nobindingwas detectedbetween SV40TAg
and βTrCP1 (data not shown).
Phosphorylation is required for the TAg–βTrCP1 interaction
βTrCP1 recognizes its target proteins through a phosphodegronwith
the consensus sequence DSpGX2–4Sp, where both serine residues are
Fig. 2. SV40 TAg does not interact with βTrCP1. Extracts of 293 and 293T cells expressing
GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF), and either JCV or SV40 early proteins,
respectively, were subjected to IP or GST pull down analyses. (A) Extracts (50 μg) of 293T
cells or 293 cells transfected with the JCVE-expressing vector were immunoprecipitated
with a mixture of PAb416 and PAb419 (anti-SV40 T) antibodies or PAb962 and
immunoblotted with a mixture of anti-T antibodies that recognize both JCV and SV40
tumor proteins. (B) GST pull down assayswere performed on extracts (500 μg) of 293 and
293T cells, and GST, GST-βTrCP1 and GST-βTrCPΔF were detected by WB using anti-GST
antibody. (C) Extracts (500 μg) of 293 and293T cellswere examined for interactions of JCV
and SV40 TAgs with GST-βTrCP1 and GST-βTrCPΔF using GST pull down analyses, and
immunoblottingwith amixtureof anti-Tantibodies (lanes 1, 4–11). Levels of JCV andSV40
TAg in the cell lines were examined by IP of cell extracts (15 μg) using anti-JCV or -SV40
TAg antibodies and WB with the mixture of anti-T antibodies (lanes 2, 3). Small proteins
recognized by the anti-GST antibody are marked with two asterisks.
Fig. 3. Phosphatase treatment abolishes the TAg–βTrCP1 interaction. 293 cells were
transfectedwithpCMV-JCVE, and 293T cellswere transfectedwith vectors expressingGST,
GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF). Extracts of 293 cells expressing the T proteins
were either treated 72 h p. t. with λ phosphatase (λPP) or left untreated. (A) 293 cell
extracts (50 μg) expressing the T proteins were either treated with λ phosphatase or left
untreatedand then immunoprecipitatedwithan anti-T antibody. Tproteinsweredetected
by WB with a cocktail of anti-T antibodies. (B) Cell extracts (600 μg) were subjected to
GST-pull down analysis and the GST-tagged proteins in 293T cells were detected with
anti-GST antibody. (C) λ phosphatase treated or untreated 293 cell extracts (600 μg)
containing the T proteins were mixed and incubated with extracts from 293T cells
(600 μg) expressing GST-βTrCP1 or GST-βTrCPΔF. Binding analyses of TAg to GST beads
(lane 1), GST-βTrCP1 (lanes 4, 6, 8) andGST-βTrCPΔF (lanes 5, 7, 9)wereperformedby the
GST pull down method. 293 cell extract (30 μg) containing TAg was immunoprecipitated
with PAb962 as a marker (lane 10), and 293T cell extracts containing the GST tagged
proteins (600 μg)were subjected toGST-pull downas controls (lanes2, 3). Bound TAgwas
detected with a cocktail of anti-T antibodies. Phosphatase treatment greatly reduced the
TAg-βTrCP interaction (lanes 8, 9).
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predicted to interact with βTrCP1, (DSGHGSS), contains three poten-
tially phosphorylatable serine residues. To examine if phosphorylation
is required for βTrCP1–TAg binding, we transfected 293 cells with
pCMV-JCVE, and 293T cells with either GST-βTrCP1 or GST-βTrCPΔF.
Since the endogenous SV40 TAg in 293T cells does not interact with
βTrCP1 (Fig. 2), we chose these cells to express GST-βTrCP1 and
GST-βTrCPΔF. The expression plasmids for the GST-tagged proteins
contain the SV40 origin of replication, therefore, their transfection into
TAg-producing cells leads to ampliﬁcation of the vector and high levels
of βTrCP1 and βTrCPΔF expression. Phosphatase treatment of 293 cell
extracts containing the JCV tumor proteins resulted in the dephosphor-
ylation of the T proteins, as evidenced by the enhancedmobility of the T′proteins on the blot (Fig. 3A). These 293 cell extracts, with or without
phosphatase treatment, were combined with extracts from 293T cells
expressing GST-βTrCP1 or GST-βTrCPΔF (Fig. 3B), and subjected to GST
pull down analyses. Phosphatase treatment of the extracts containing
the T proteins greatly reduced the interaction of TAg with βTrCP1 and
βTrCPΔF (Fig. 3C, lanes 8, 9; respectively), demonstrating that
phosphorylation of TAg is required for the interaction between the
viral and cellular proteins.
Serine 640 in the JCV TAg is essential for binding βTrCP1
The two serines in the destruction motif of known βTrCP1 substrates
must be phosphorylated for recognition by the F-box protein (Cardozo
and Pagano, 2004). To identify the serine residue(s) in the JCV TAg
destructionmotif required for bindingβTrCP1,we substituted each serine,
either singly or in combination (Fig. 4), with alanine (e.g., Ser640 to Ala;
S640A) and examined the ability of the mutant TAgs to interact with
βTrCP1. U87MG cells were co-transfected with the GST-βTrCP1 or
GST-βTrCPΔF expression plasmids and pCMV-JCVE constructs expressing
either WT or mutant TAg. Equivalent expression levels of the WT and
mutant T proteins in U87MG cells suggest themutations do not affect the
stability of any of the viral tumor proteins (Figs. 4A, B, E, F).Western blots
demonstrated the expression of the GST tagged βTrCP proteins
(Figs. 4C, G). GST pull down analyses indicated that mutation of serine
640 severely reduces the interaction of TAg with βTrCP1 and βTrCPΔF
Fig. 4. Amino acids serine 640 and 644 inﬂuence TAg binding to βTrCP1. pCMV-JCVE constructs carrying TAg single point mutations S640A, S644A, S645A, or double point mutations
S640A–S644A, S640A–S645A or S644A–S645A, and GST, GST-βTrCP1 or GST-βTrCPΔF (GST-ΔF)were co-transfected into U87MG cells, and extracts were collected 72 h p. t. for IP and GST
pull down analyses. (A, E) Expression levels of theWT, single and doublemutant T antigenswere analyzed using extracts (50 μg) immunoprecipitatedwith PAb962. The T proteins in cells
expressingGST-βTrCP1 (A, E), orGST-βTrCPΔF (B, F),weredetectedwith a cocktail of anti-T antibodies. (C, G)GSTpull downanalysis of cell extracts (600 μg)was performed to analyze the
expression levels of GST, GST-βTrCP1 and GST-βTrCPΔF. The GST-tagged proteins were detected with α-GST antibody. (D, H) A GST pull down assay was performed on cell extracts
(600 μg) and wild type or mutant TAgs bound to GST-βTrCP1 (D, lanes 4–7; H, lanes 4–8) and GST-βTrCPΔF (D, lanes 8–11; H, 9–13) were detected by WB with a cocktail of anti-T
antibodies.Mutationof serine 640of JCVTAggreatly reduced the TAg-βTrCP interaction (D, lanes 5, 9).Doublemutant constructs containingamutation at serine640of JCV TAgalsogreatly
reduced the TAg-βTrCP interaction (lanes 5–7, 10–12) (H). U87MG cell extracts (30 μg) containing WT JCVE were immunoprecipitated with PAb962 as a size marker (D and H, lane 2).
Mock-transfected U87MG cells were used as a control (Con) (D and H, lane 1). Small proteins recognized by the anti-GST antibody are marked with two asterisks.
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Fig. 5. JCVTAg interactswithβTrCP2.U87MGcellswereco-transfectedwithpCMV-JCVE or
the pCMV-JCVE construct carrying the TAg pointmutation S640A, and GST, GST-βTrCP1 or
GST-βTrCP2 plasmids. Cell extracts were prepared 72 h p. t. for IP and GST pull down
analyses. (A) Cell extracts (50 μg) were immunoprecipitated with anti-T antibody
(PAb962) and viral proteins were visualized by WB, using an anti-T antibody cocktail.
(B) Extracts (500 g)wereanalyzed for the expression ofGST,GST-βTrCP1 andGST-βTrCP2
using the GST pull down assay followed by WB with an anti-GST antibody. (C) The
interactions of WT and mutant TAg with βTrCP2 were detected by performing GST pull
downs of cell extracts (500 μg) and immunoblotting with an anti-T antibody cocktail
(lanes 1, 4–8). Cell extracts (30 μg) containing WT TAg and mutant TAg were
immunoprecipitated with PAb962 followed by WB with an anti-T antibody cocktail
(lanes 2, 3). Mock-transfected U87MG cells were used as a control (Con; lane 1).
Small proteins recognized by the anti-GST antibody are marked with two asterisks.
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644 and 645 do not (Fig. 4D, lanes 6, 7, 10, 11; Fig. 4H, lanes 8, 13).We did
note; however, thatmutant S644A consistently exhibited slightly reduced
binding to βTrCP1 and βTrCPΔF (Fig. 4D, lanes 6, 10). These data indicate
that serine 640, and to amuch lesser extent, serine 644, are involved in the
interaction between TAg and βTrCP1.
TAg interacts with βTrCP2
βTrCP2 shares 86% amino acid identity with βTrCP1, and both
proteins recognize the phosphodegron, found in several common
substrates, that contains the sequence DSpGX2–4Sp. However, the two
proteins do exhibit functional differences, including the recognition of
unique cellular targets and different subcellular localization patterns
(Kumar et al., 2003; Li et al., 2004). βTrCP1 is mainly found in the
nucleus, whereas βTrCP2 localizes to the cytoplasm, suggesting that
βTrCP1 promotes degradation of nuclear substrates, and βTrCP2 targets
cytoplasmic substrates. Since some cellular targets, such as β-catenin or
IkB, aswell as theHIV viral protein Vpu, are known to interactwith both
βTrCP1 and βTrCP2 (Fuchs et al., 1999; Mangeat et al., 2009), we
determined whether TAg binds βTrCP2 by performing GST pull down
analyses on cell extracts expressing GST βTrCP2 and either WT or
mutant TAg. WB analyses demonstrating the expression levels of the T
proteins (Fig. 5A), and the GST-tagged βTrCP1 and βTrCP2 (Fig. 5B) are
shown. Our GST pull down analysis conﬁrmed that TAg interacts with
βTrCP2 (Fig. 5C, lane 6), and that serine 640 of TAg is required for this
binding (Fig. 5C, lane 8).
TAg co-localizes with βTrCP1 and βTrCP2 in the cytoplasm
βTrCP1 and polyomavirus TAgs are found predominantly in the
nucleus, although a small percentage of these proteins is detected in the
cytoplasm (Davis et al., 2002; Soule and Butel, 1979). βTrCP2 is mainly a
cytoplasmicprotein (Davis et al., 2002). Todetermine if TAgandβTrCP1or
βTrCP2 co-localize in the cell, double immunoﬂuorescence staining was
performed. U87MG cells were co-transfected with pCMV-T+/t−/T′− and
either the GST-βTrCP1 or GST-βTrCP2 plasmids. Cells were stained with
antibodies directed against the T protein or GST, and the subcellular
localization of the viral or GST-tagged protein was analyzed by confocal
microscopy. As expected, nuclear ﬂuorescence predominated in cells
expressing JCV TAg in the absence of GST-βTrCP1 (Fig. 6A) and in cells
expressing GST-βTrCP1 in the absence of TAg (Fig. 6B). Some cytoplasmic
staining couldbedetected in the latter case. Cytoplasmicﬂuorescencewas
detected exclusively in cells expressing GST-βTrCP2 in the absence of TAg
as reported (Davis et al., 2002) (Fig. 6D).WhenTAg andGST-βTrCP1were
co-expressed, the majority of cells exhibited TAg staining in both the
nucleusandcytoplasm, and the twoproteins co-localized in thecytoplasm
(Fig. 6C).When TAg and βTrCP2were expressed together, co-localization
was exclusively cytoplasmic, and TAg staining was observed in both
nuclear and cytoplasmic compartments (Fig. 6E).
Similarly, we analyzed the subcellular co-localization of TAg in the
presence of βTrCPΔF, which lacks the F-box domain. Deletion of the F
box inhibits the ability of βTrCP to interact with the components of the
degradation complex Skp1, Cul1 and Roc1. While still capable of
interacting with its target proteins, βTrCPΔF can no longer degrade
them. As expected, βTrCPΔF localizes in the nucleus when expressed
independently (Sadot et al., 2000) (Fig. 6F). Interestingly,when TAg and
βTrCPΔF were co-expressed, the two proteins co-localized only in the
cell nucleus, and no cytoplasmic ﬂuorescence was detected for TAg
(Fig. 6G), suggesting that the cytoplasmic localization of TAgdependson
βTrCP and βTrCP's ability to interact with other members of the SCF
complex. This data also suggests βTrCP must interact with members of
the SCF complex to induce its proper cytoplasmic translocation. Similar
results were obtained in three independent experiments inwhichmore
than 100 individual cells were examined.The TAg-βTrCP interaction does not signiﬁcantly affect the levels of the
βTrCP substrate β-catenin
β-catenin is one of several cellular proteins targeted for degradation
by SCFβTrCP, and its recognition as a substrate requires phosphorylation
of serines 33and37 residingwithin thephosphodegronboundbyβTrCP
(Kimelman and Xu, 2006). TAg has been reported to interact with
β-catenin and to promote its stabilization (Gan and Khalili, 2004). We
hypothesized that this TAg function might be mediated through its
interactionwith βTrCP. U87MG cells were transfected with pCMV-JCVE,
or pCMV-JCVE constructs encoding the S640A, S644A or S645A mutant
Fig. 6. Co-localization of TAg and βTrCP. U87MG cells were transfected with 1 μg of plasmid encoding TAg and/or GST-βTrCP1, GST-βTrCP2 or GST-βTrCPΔF. Cells were ﬁxed and
immunostained with anti-T and anti-GST antibodies 48 h p. t. (A) Cells expressing TAg only show nuclear localization. (B) GST-βTrCP1, when expressed alone, is found in both cellular
compartments, but predominantly in thenucleus. (C) Co-expression of TAg andGST-βTrCP1, results in co-localization of the proteins primarily in the cytoplasm. Strongnuclear staining for
TAg was also observed in these cells. (D) βTrCP2 localizes in the cytoplasm. (E) Co-expression of TAg with βTrCP2 promotes relocalization of TAg to the cytoplasm. (F) βTrCPΔF localizes
mainly in the nucleuswhen expressed alone. (G)When co-expressed, TAg andβTrCPΔF co-localize in the nucleus, and no cytoplasmic TAg staining is detected. Quantitative assessment of
co-localization resulted in a Pearson's Coefﬁcient varying between 0.97 and 0.99 for all the images.
124 M.M. Reviriego-Mendoza, R.J. Frisque / Virology 410 (2011) 119–128TAgs, and TAg and β-catenin levels were examined by WB analysis
(Figs. 7A, B). We observed, as predicted, that endogenous β-catenin
levels in cells expressing the S640A mutant TAg were similar to those
found in untransfected cells (Fig. 7B, lane 3 vs. 1). However, in cells
producing WT TAg, we did not observe a signiﬁcant elevation of
β-catenin (Fig. 7B, lane 2). Similar results were obtained when theexperiment was repeated in PHFG cells or the human colon cancer cell
line RKO, andwith vectors expressing exogenousmyc-taggedβ-catenin
(data not shown). These data fail to support our prediction that JCV TAg
stabilizes β-catenin by interfering with βTrCP-induced degradation,
since i) the inability of mutant TAg to bind βTrCP does not result in
decreased levels of β-catenin relative to that measured using WT TAg
Fig. 7. Interaction of TAg and endogenous βTrCP does not alter β-catenin levels. U87MG
cells were transfected with 8 μg of the wild type pCMV-JCVE plasmid, or with constructs
expressingmutant T proteins altered at serine 640, 644 or 645. Cell extractswere analyzed
at 48 h p.t. (A) Expression of T proteins in U87MG cells were detected by IP of cell extracts
(50 μg) with PAb962, and immunoblotting with a cocktail of anti-T antibodies. (B) Cell
extracts (30 μg) were subjected to WB, and endogenous β-catenin was detected with an
anti-β-catenin antibody. Lane 1 shows the endogenous levels of β-catenin in cells
transfected with pCR3 vector as a control. Endogenous β-catenin levels in the presence of
WT or mutant TAgs correspond to lanes 2 through 5. The blots were stripped and re-
probed for β-actin with anti-β-actin antibody as a loading control. Relative differences in
β-catenin levels between extracts were determined by normalizing β-catenin values to
actin levels using the ImageJ program. Based upon these calculations, a value of 1.0 was
arbitrarily assigned to JCVE-transfected cells. The relativeβ-catenin levels observed in cells
expressing the S640A was 0.9 (B, lane 3).
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β-catenin (Gan and Khalili, 2004), an observation upon which our
hypothesis was formulated.
Discussion
Our study reveals a new activity for JCV TAg that links this tumor
protein to the SCFβTrCP1/2 destruction machinery. Interestingly, a
potential βTrCP recognition domain is also present in the TAgs of the
human BK and Merkel cell polyomaviruses (amino acids 640–646;
amino acids 811–817), respectively, but not in two other recently
discovered human polyomaviruses, KIV and WUV. Viruses have
developed strategies to hijack key cellular processes to initiate their
own replication cycles. Recently, much attention has focused upon the
ability of tumor viruses to interfere with a cell's ubiquitination and
degradation systems (Shackelford and Pagano, 2004). Welcker and
Clurman (2005) described a phosphorylation-dependent interaction of
SV40 TAg with the F-box protein, Fbw7, the substrate recognition
subunit of the SCFFbw7 ubiquitin ligase complex. This interaction
decreases the turnover of at least one known SCF Fbw7 substrate, cyclin
E, resulting in enhanced activity of cyclinE-Cdk2 kinase (Welcker and
Clurman, 2005). SV40 TAg has also been found to interact with Cul7, a
subunit of a SCF-like E3 ligase complex (Ali et al., 2004; Kasper et al.,
2005; Kohrman and Imperiale, 1992). Cul7 interacts with Fbwx8, Roc1andSkp1 (Ali et al., 2004;Kasper et al., 2005) to target theubiquitination
and degradation of cyclin D1 and IRS-1 (Okabe et al., 2006; Xu et al.,
2008). TAg mutations that abolish Cul7 binding result in a transforma-
tion-defective virus.
Tumor proteins of the human papillomaviruses, HPV-16 and -18,
also facilitate proteasomal degradation of cellular proteins. The E6
protein of these high riskHPV types recruits the cellular ubiquitin ligase,
E6-associated protein (E6AP) (Howley, 2006). The E6–E6AP complex
interacts with p53 to promote the polyubiquitination and degradation
of this tumor suppressor. This event reveals a mechanism whereby a
viral protein facilitates the recognition of a new target substrate by an
ubiquitin ligase complex. A second HPV tumor protein, E7, targets pRB
and recruits the ubiquitin conjugating enzyme, E2–25K, resulting in the
degradation of this tumor suppressor (Howley, 2006; Oh et al., 2010).
βTrCP has been shown to be a cellular target of HIV (Besnard-Guerin
et al., 2004;Bouret al., 2001;Estrabaudet al., 2007;Margottin et al., 1998).
The HIV Vpu protein acts as pseudo-substrate by interacting with βTrCP1
and bringing the degradation machinery in close proximity to substrates
that include the CD4 receptor. This bridging action of Vpu results in
recognitionofCD4byβTrCP1and theproteasomaldestructionof theT cell
receptor (Margottin et al., 1998). The CD4 sequence does not contain the
βTrCP1 consensus motif, suggesting that Vpu promotes βTrCP1 recogni-
tion and degradation of a new substrate. In contrast, the Vpu-βTrCP1
interaction inhibits the degradation of some authentic βTrCP1 substrates,
such as β-catenin, ATF4, IkB and CdC25A (Besnard-Guerin et al., 2004;
Bouret al., 2001;Estrabaudet al., 2007). Further, Emi1, yet anotherβTrCP1
substrate, remains unaffected by the Vpu–βTrCP1 interaction. These
ﬁndings indicate that Vpu directs βTrCP1 tomultiple substrates that may
be differentially affected by each interaction (Estrabaud et al., 2007).
In this study we found that JCV TAg, but not the related SV40 TAg,
binds toβTrCP1 andβTrCP2, and that this interaction is phosphorylation
dependent. Binding requires a destruction motif within the C-terminus
of TAg that includes a serine residue at position 640. A second serine at
position 644 appears to make a small contribution to TAg–βTrCP1bind-
ing. The observation that just one serine within the destruction motif is
required for βTrCP binding highlights a difference between TAg and
other known βTrCP substrates for which two phosphorylated serines
are required (Cardozo and Pagano, 2004). In addition, JCV TAg stability
was not altered detectably by its interaction with the F-box protein,
suggesting TAg acts as a pseudo-substrate (Margottin et al., 1998),
bringing βTrCP in close proximity to potential target proteins without
being degraded itself.
Our immunoﬂuorescence data indicate that TAg andβTrCP co-localize
when expressed in the same cell. The polyomavirus TAgs have a strong
nuclear localization signal and are predominantly found in the nucleus;
only a small amount of TAg is found in the cytoplasm (Soule and Butel,
1979). Subcellular localization ofβTrCP1 andβTrCP2 has beendetected in
the nucleus and cytoplasm, respectively (Davis et al., 2002; Fuchs et al.,
1999), and our results support this observation. Upon overexpression of
βTrCP in cells, TAg staining became readily apparent in the cytoplasm.
Additionally, while βTrCP2 remains cytoplasmic in the presence of TAg,
signiﬁcant βTrCP1 staining is redirected from the nucleus to the
cytoplasm, where the cellular and viral proteins co-localize. The
relocalization of TAg and βTrCP1 to the cytoplasm might be substrate-
dependant. It has been shown that the nucleo-cytoplasmic shuttling of
βTrCP1 is regulated by its nuclear binding to the pseudo-substrate,
hnRNP-U. High afﬁnity βTrCP1 substrates compete with hnRNP-U for
binding, leading to the release of active βTrCP1 that may then target
nuclear or cytoplasmic targets for subsequent degradation (Davis et al.,
2002; Fuchs et al., 2004). The co-localization of TAg and βTrCP1 in the
cytoplasmic compartment might indicate that TAg successfully competes
with hnRNP-U in the nucleus for βTrCP1 binding, resulting in the
cytoplasmic localization of the two proteins and subsequent degradation
of a targeted substrate (Davis et al., 2002).
F-boxproteins, includingβTrCP, are characterized by the presence of
two conserved regions; the WD repeats, which are essential for
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enables βTrCP to interact with Skp1, Cul1 and Roc1 (Fuchs et al., 2004).
We detectedβTrCPΔF, aswell asβTrCP1, in the nuclear compartment as
already reported (Sadot et al., 2000). Our immunoﬂuorescence data
show that TAg and βTrCPΔF, co-localize exclusively in the nucleus. It is
noteworthy that no cytoplasmic relocalization of TAg was detected in
cells expressing βTrCPΔF. The SCF complex members Cul1, Skp1 and
Roc1 are detected in both the nucleus and cytoplasm, and it is suggested
that their recruitment to the nucleus occurs upon activation of the SCF
complex (Andrews et al., 2006; Boyer et al., 2004; Furukawa et al.,
2000). Our data suggest that the cytoplasmic localization of TAg in the
presence of βTrCP requires a functional SCFβTrCP complex. This
observation, together with the ﬁnding demonstrating cytoplasmic
relocalization of βTrCP1and TAg, point to the possibility that the
cytoplasmic shuttling of theproteins requiresβTrCP to interact, not only
with its substrates as already proposed (Davis et al., 2002), but alsowith
the other members of the degradation complex.
TAg has been reported to stabilize β-catenin, a known βTrCP1
substrate (Bhattacharyya and Khalili, 2007; Gan and Khalili, 2004;
Kimelman and Xu, 2006), thereforewe investigatedwhether TAg binding
to βTrCP inﬂuences β-catenin stability. As previously reported (Gan and
Khalili, 2004), an interactionbetweenTAg and endogenousβ-cateninwas
detected (data not shown). However, onlyminor differences in the levels
of β-catenin were detected in cells expressing WT vs. the mutant S640A
TAg. We are unable to explain the discrepancy between our results and
those previously reported (Bhattacharyya and Khalili, 2007; Gan and
Khalili, 2004); however, our data indicate that if TAg does stabilize this
critical component of theWnt pathway, it is not due to its ability to block
βTrCP function.
β-catenin, has been identiﬁed as an important target in the process
of TAg-induced cellular transformation. Other targets potentially
affected by the TAg–βTrCP interaction remain to be explored. In
addition to their inﬂuence upon the G1/S phase transition of the cell
cycle, polyomaviruses promote cell cycle arrest at the G2/M phase
(Davy and Doorbar, 2007). JCV TAg induces G2 arrest as a result of the
activation of the ATM and ATR checkpoint pathways, thereby
promoting viral replication in permissive cells (Orba et al., 2010).
βTrCP1 is a key player in the S and G2 DNA damage checkpoint
pathways, and it promotes cell cycle arrest following DNA damage by
attenuating CDK1 activity through degradation of Cdc25A. Addition-
ally,βTrCP1 has been shown to restore cell cycle progression and entry
into mitosis by facilitating the degradation of claspin and WEE1
(Branzei and Foiani, 2008). One might speculate that the TAg–βTrCP1
interaction contributes to one or more of these cell cycle events.
We have identiﬁed for the ﬁrst time a link between JCV TAg function
andamechanismof proteasomedegradation in the cell.Wehavenot yetTable 1
Site-directed mutagenesis and RT-PCR primers.
Primer Name Sequencea
1.JCVES640AFwd 5′-CTGAAGCAGAAGA
2.JCVES640ARev 5′-CTTGATCCATGTCC
3.JCVES644AFwd 5′-GACTCTGGACATGG
4.JCVES644ARev 5′-GTGATTCAGTGCTT
5.JCVES645AFwd 5′-CTCTGGACATGGAT
6.JCVES645ARev 5′-GATTGTGATTCAGT
7.JCVES640A–S644AFwd 5′-GACGCTGGACATGG
8.JCVES640A–S644ARev 5′-GTGATTCAGTGCTT
9.JCVES640A–S645AFwd 5′-CTGAAGCAGAAGA
10.JCVES640A–S645ARev 5′-CTGATCCATGTCCA
11.JCVES644A-S645AFwd 5′-GACTCTGGACATGG
12.JCVES644A–S645ARev 5′-GTGATTCAGTGGCT
a Single point mutations in the destruction motif (primers 1–6) were introduced into pCM
were changed to alanine (altered nucleotides are in bold). Double point mutations (primer
create the double mutant S640A-S644A (primers 7, 8), and single mutant pCMV-JCVE(S645A
S645A (primers 11, 12). New altered nucleotides are in bold and pre-existing mutations ar
b Nucleotide numbers are based upon the JCV(Mad1) sequence (Frisque et al., 1984).identiﬁed a target affected by the TAg–βTrCP interaction; however,
preliminary data in our laboratory reveal that mutation of serine 640
within TAg's destruction motif signiﬁcantly reduces JCV replication late
in infection (Reviriego-Mendoza and Frisque, unpublished data). This
ﬁnding highlights a potential function of βTrCP in the JCV life cycle.
Given the oncogenic potential of JCV and the increasing evidence of the
involvement of the ubiquitin proteasomal pathways in cell growth and
transformation (Frescas and Pagano, 2008; Fuchs et al., 2004), it will be
important to identify the cellular proteins targeted by the JCV
TAg–βTrCP interaction to better understand the oncogenic and
pathogenic potential of this human polyomavirus.
Materials and methods
DNA constructs
The pCMV-JCVE vector, which expresses the JCV early coding region,
and the pCMV-T+/t−/T′− vector, which expresses TAg only, were
described earlier (Bollag et al., 2006, 2010). The single mutants pCMV-
JCVE(S640A), pCMV-JCVE(S644A) andpCMV-JCVE(S645A) and thedouble
mutants pCMV-JCVE(S640A-S644A), pCMV-JCVE(S640A-S645A) and
pCMV-JCVE(S644A-S645A) were created by PCR-based site-directed
mutagenesis with primers identiﬁed in Table 1. The pDEST27, pGST-
βTrCP1, pGST-βTrCP2 and pGST-βTrCPΔF constructs were gifts from Dr.
Wade Harper (Westbrook et al., 2008).
Cells, extracts and DNA transfections
U87MG cells were grown in minimum essential Eagle's medium
(MEM) supplemented with 10% fetal bovine serum (FBS), 2% sodium
pyruvate, 1% essential amino acids, 2 mM L-glutamine, penicillin G
(100 U/ml) and streptomycin (100 μg/ml). The human embryonic
kidney cell lines 293 and 293T cells were cultured in Dulbeccomodiﬁed
Eagle medium (DMEM) supplemented with 10% FBS, L-glutamine,
penicillin G (100 U/ml) and streptomycin (100 μg/ml). U87MG cells
were incubated at 37 °C in 10% CO2, and 293, 293T cells were incubated
at 37 °C in 5% CO2.
Transient transfections and co-transfections were carried out with
lipofectamine 2000 following themanufacturer's instructions (Invitrogen,
Carlsbad, CA). Brieﬂy, 5×105 cells were plated on 60 mm tissue culture
plates, and transfected 24 h after seedingwith 1 μg (8 μg for the detection
of endogenous β-catenin) of each of the DNA constructs. Cell extracts
prepared as previously described (Bollag, et al., 2006),were obtained 72 h
post-transfection (p.t.) for binding analyses, and 48 h p.t. for the detection
of endogenous β-catenin.Nucleotidesb
CGCTGGACATGGATCAA-3′ 2766–2737
AGCGTCTTCTGCTTCAG-3 2736–2766
AGCAAGCACTGAATCAC-3′ 2755–2725
GCTCCATGTCCAGAGTC-3′
CAGCCACTGAATCACAATC-3′ 2753–2721
GGCTGATCCATGTCCAGAG-3′
AGCAAGCACTGAATCAC-3′ 2755–2725
GCTCCATGTCCAGCGTC-3′
CGCTGGACATGGATCAG-3′ 2766–2737
GCGTCTTCTGCTTCAG-3′
AGCAGCCACTGAATCAC-3′ 2755–2725
GCTCCATGTCCAGAGTC-3′
V-JCVE. Serines 640 (primers 1and 2), 644 (primers 3 and 4) and 645 (primers 5 and 6)
s 7 to 12) were produced by using single mutant pCMV-JCVE(S640A) as a template to
) as a template to create the double mutants S640A-S645A (primers 9, 10) and S644A-
e underlined.
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Monoclonal anti-T antibodies PAb962, PAb2000, PAb2001, PAb2003,
PAb2024 and PAb2030 (Bollag and Frisque, 1992; Bollag et al., 2000;
Tevethia et al., 1992)were used to detect JCV tumor proteins. PAb416 and
PAb419 were used to detect SV40 T proteins (Harlow et al., 1981).
GST-tagged proteins and β-actin were detected with rabbit anti-GST
antibody (1:5000) and anti-β-actin (1:5000) (Sigma-Aldrich, St. Louis,
MO), respectively. Mouse anti-β-catenin (E-5) (1:300) (Santa Cruz
Biotechnologies, Santa Cruz, CA) was used to detect endogenous β-
catenin. Protein bands were visualized with secondary antibodies
conjugated to either alkaline phosphatase (Sigma) or horseradish
peroxidase (Cell Signaling Technology, Danvers, MA).
Immunoprecipitation and GST pull down experiments
The detection of the T proteins was performed by immunoprecipita-
tion (IP) as described earlier (Bollag et al., 2006). GST pull down assays to
detect GST-tagged βTrCP1, GST-βTrCP2 and βTrCPΔF, and to analyze
βTrCP–TAg interactions were described elsewhere (Westbrook et al.,
2008).
Phosphatase treatment
λ-phosphatase treatment of 293 cell extracts was performed
according to the manufacturer's instructions (New England Biolabs,
Ipswich,MA). 293 cells transfectedwith pCMV-JCVEwere lysed 72 h p.t.
with EBC lysis buffer (50 mM Tris, pH 8.0, 120 mM NaCl, 0.5% NP-40)
supplemented with protease inhibitors (2 μg/ml leupeptin, 2 μg/ml
E-64, 1 μg/ml aprotinin and 0.25 mM pefabloc). Extracts were treated
withλ-phosphatase for 25 min at 30 °C. The reactionwas terminated by
adding 10 mM Na3VO4 and 50 mM NaF.
Immunoﬂuorescence staining
U87MG cells (3.5×105 ) were seeded on coverslips. After 48 h p.t.,
cells grown on coverslips were ﬁxed with 4% paraformaldehyde for
20 min, andpermeabilizedwith 0.02% TritonX-100 for 5 min. Cellswere
incubated with blocking solution (10% heat-inactivated goat serum)
(Millipore, Billerica, MA) for 45 min. Subsequently, cells were incubated
with a cocktail of anti-T antibodies (PAb962, PAb2001, PAb2003,
PAb2024 and PAb2030; 1:250) for 1 h. Cells were washed with PBS
and incubated for 30 minwithgoat anti-mouseAlexaFluor594(1:1000)
(Invitrogen). Cells were washed with PBS and incubated with blocking
solution for 45 min prior to incubating with mouse anti-GST antibody
(1:2000). Goat anti-mouse Alexa Fluor 488 (1:1000) (Invitrogen) was
used as a secondary antibody. Double and single immunostainings were
performed on cells that did not express TAg nor GST-βTrCP (negative
controls; data not shown). Immunostained cells were viewed under a
confocal microscope (Olympus FV1000 Laser Scanning Confocal Micro-
scope, InvertedOlympus IX-81. Cytometry Facility, Huck Institutes of the
Life Sciences, Penn State University), using the FV10-ASW version 1.7
analyzing software. Sequential scans were used for all images.
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